US EditionPublished • loading... • Updated
Eli Lilly Lowers Weight-Loss Drug Zepbound Prices After Trump Deal
Eli Lilly reduces Zepbound vial prices to as low as $299 on LillyDirect to improve affordability following government deals and rival discounts, aiding cash-paying patients.
- On Dec 01, 2025, Eli Lilly & Co. cut cash prices for single-dose Zepbound vials on LillyDirect to $299–$449 from $349–$499 for direct consumers.
- After rival discounts earlier this month, Lilly's price cuts follow last month's Trump administration deals to lower government costs for GLP-1 drugs and expand access.
- Because single-dose vials are cheaper to make, Lilly noted direct-to-consumer sales now account for over a third of new prescriptions and cut vial prices twice this year on LillyDirect amid pricing competition with Novo Nordisk.
- Amid still-high list prices, Eli Lilly shares fell nearly 1% in premarket trading while Novo Nordisk's stock dropped more than 1.7%, with Zepbound's list price at roughly $1,086 per month.
- Looking ahead to Medicare rollout, the Nov. 6 deal said Medicare would cover Zepbound and sell the multi‑dose pen at an average price of $245 per monthly dose, with a $50 copay for eligible recipients.
Insights by Ground AI
12 Articles
12 Articles
Weight-Loss Drug Zepbound Cost Drops To $299 A Month After Trump Deal
Topline Eli Lilly on Monday lowered the cost of Zepbound after the pharmaceutical giant and Ozempic maker Novo Nordisk announced a deal with the Trump administration to slash the prices of the popular weight-loss drugs. Key Facts The out-of-pocket monthly price for the lowest single-dose vial of…
Coverage Details
Total News Sources12
Leaning Left3Leaning Right0Center4Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
L 43%
C 57%
Factuality
To view factuality data please Upgrade to Premium
